Results 171 to 180 of about 26,505 (287)

Effectiveness and Safety of Fixed‐Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real‐World Study From China

Journal of Diabetes, Volume 18, Issue 10, October 2026.
This large‐scale real‐world Chinese study demonstrates glycemic clinical control rates (HbA1c > 7%) at baseline and 6 months across key subgroups, including age, baseline HbA1c, body mass index, and treatment regimen. In this prospective real‐world study of fixed‐dose combination metformin and empagliflozin in Chinese patients with type 2 diabetes ...
Weijian Ke, Yinghong Kong, Songbo Fu, Liyun Wang, Ying Pan, Shao Zhong, Yanhua Jiang, Hui Chen, Xuehua Jiao, Fuxing Sha, Liwu Xu, Wei Shao, Fenghua Lan, Xiaoli Chen, Bo Yan, Guangju Zhou, Ping Shi, Fen Li, Huike He, Hong Li, Guangwu Zhang, Hongyu Duan, Fang Wang, Weikun Gong, Yuxiao Bai, Bin Wang, Xin Mou, Liying He, Wukun Ma, Junhua Song, Juan Zheng, Xiaosu Bai, Xiaosi Li, Xin Yan, Yanqiu Wang, Zhenhua Wang, Juan Yuan, Wei Lu, Yuan Liang, Yufan Wang, Fenjuan Xu, Xuefeng Li, Xuan Lin, Hongbin Zhu, Lingling Xu, Xiaojia Lou, Lingxiao Wang, Lijuan Cui, Lijun Wang, Hua Qian, Yuwen Shi, Yanbing Li   +51 more
wiley   +1 more source

Syndromic diabetes and hypergonadotropic hypogonadism in a boy with a 12q24.31-32 chromosomal deletion involving <i>HNF1A</i>, <i>DHX37</i>, and <i>SETD1B</i>. [PDF]

Clin Pediatr Endocrinol
Nakagawa T, Dai Saito, Shima H, Kawashima S, Suzuki D, Togashi N, Kikuchi A, Kanno J.   +7 more
europepmc   +1 more source

Human β‐Cell Dedifferentiation and Diabetes

Journal of Diabetes, Volume 18, Issue 10, October 2026.
Human β‐cell dedifferentiation is inversely associated with HOMA‐β and occurs in Type 2 diabetes, Type 3c diabetes, and age‐related diabetes, potentially before hyperglycemia develops. Progressive loss of β‐cell identity is accompanied by dedifferentiation and transdifferentiation, suggesting that reversing these cell‐state changes may help restore ...
Jiajun Sun, Jinsook Son, Qidi Wang
wiley   +1 more source

Myoprotective Fat-Loss Phenotypes in Obesity-Associated Type 2 Diabetes: A 12-Month Real-World Cohort Study of Metformin-Based Treatment Regimens. [PDF]

Clin Pract
Bujdei-Tebeică I, Pantea-Stoian AM, Mihai DA, Ștefan SD, Serafinceanu C.   +4 more
europepmc   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Synthesis, Herbicidal Activity Evaluation, and Molecular Docking of Novel Acylthioureas as AHAS Inhibitors. [PDF]

Molecules
Jiang B, Chen X, He X, Chai Y, Wang Y, Li R.   +5 more
europepmc   +1 more source

Under‐ and overdosing insulin in the hospital: A retrospective cohort study of dose deviation and patient outcomes

Diabetic Medicine, Volume 43, Issue 10, October 2026.
Abstract Aims Glycaemic abnormalities during hospitalization are common and linked to morbidity and mortality, yet little is known about how deviations from guideline‐recommended insulin dosing affect outcomes. The aim of this study is to examine whether deviation from an expected insulin dose in non‐critically ill hospitalized adults with type 2 ...
Hussein Zaitoon, Sher Matsri, Shira Nagler, Matteo M. Lalovich, Ralph A. DeFronzo, Eugene Feigin   +5 more
wiley   +1 more source

Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. [PDF]

BMJ Open
Hong SH, Lee H, Lee SY, Sung YA, Hong YS, Song DK, Jung H, Kim MH.   +7 more
europepmc   +1 more source

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9607-9620, October 2026.
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji, Jonas Dahl Andersen, Malik Benamar, Paola Ponzani, A. G. Unnikrishnan, Siri Vinther, Rosangela Rea   +6 more
wiley   +1 more source

Blamed but not at fault: anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists. [PDF]

Korean J Anesthesiol
Kwak HJ, Choi JJ, Lee D, Jo YY.
europepmc   +1 more source